CD30+ T-cell lymphoma following Chimeric Antigen Receptor T-cell therapy (CART-cell therapy): Diagnostic uncertainty in a postimmunotherapy setting. [PDF]
McClanahan M, Stokes M.
europepmc +1 more source
HHV‐8/KSHV in Solid Organ Transplantation: Current Gaps of Knowledge and Future Directions
Risk mitigation strategies, including donors/recipients screening, DNAemia monitoring in recipients at risk, CNI‐to‐mTOR inhibitors switch, antivirals, and rituximab for KICS, may mitigate the impact of HHV‐8/KSHV infection in SOT. This review provides an update on KICS, identifies research gaps, and summarizes advances in screening and management ...
Alessandra Mularoni +9 more
wiley +1 more source
Association of Secondary Primary Malignancies in Cutaneous Lymphoma: A Narrative Review. [PDF]
Hung YH, Hsiao PF.
europepmc +1 more source
Real-World Insights Into the Clinical Characteristics and Survival Outcomes of Extranodal Peripheral T-Cell Lymphomas: A Multiethnic Asian Cohort Study. [PDF]
Neo RYS, Chang EWY, Lim ST, Chan JY.
europepmc +1 more source
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential
M. Duvic, M. Evans, Casey Wang
semanticscholar +1 more source
Treatment of Reactive Histiocytosis With Oclacitinib: A Retrospective Case Series of 10 Dogs
Background: Canine reactive histiocytosis is a proliferative disorder of activated interstitial dendritic cells with cutaneous and systemic forms. An immune‐mediated aetiology is likely, and systemic immunomodulatory agents such as corticosteroids, tetracycline/niacinamide, ciclosporin, azathioprine and leflunomide have been employed for its management.
Christine L. Cain +2 more
wiley +1 more source
A Case of Lymphomatoid Papulosis With CD15- and CD30-Positive Reed-Sternberg-Like Cells in CD8-Positive Mycosis Fungoides: Differential Diagnosis of Secondary Hodgkin Lymphoma and Large Cell Transformation of Mycosis Fungoides. [PDF]
Sakiyama T, Shirase T, Furuta K.
europepmc +1 more source
What's new? Adult T‐cell leukemia/lymphoma (ATL) is a rare and aggressive malignancy caused by human T‐cell leukemia virus type 1 (HTLV‐1). The authors comprehensively analyzed the epidemiological and clinical features of ATL over a 30‐year period in French Guiana, a region with high HTLV‐1 endemicity and a multiethnic population.
Jill‐Léa Ramassamy +16 more
wiley +1 more source

